Study of cell dose and storage time on engraftment of cryopreserved autologous bone marrow in a canine model.

Clinical and pathological findings in dogs following supralethal total body irradiation with and without infusion of autologous long-term marrow culture cells. Can J Vet Res (1993) 1.11

Cyclophosphamide treatment expands the circulating hematopoietic stem cell pool in dogs. J Clin Invest (1981) 0.97

High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. Expert Rev Anticancer Ther (2011) 0.89

A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematol Oncol Clin North Am (2011) 0.82

Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model. Vet Comp Oncol (2007) 0.79

The use of an implantable central venous (Hickman) catheter for long-term venous access in dogs undergoing bone marrow transplantation. Can J Vet Res (1992) 0.78

Autologous peripheral blood hematopoietic cell transplantation in dogs with T-cell lymphoma. J Vet Intern Med (2014) 0.76

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood (2000) 9.60

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55

Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med (1998) 5.98

Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59

All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med (1997) 4.79

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med (1993) 3.18

Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97

Hematologic malignancies and other marrow failure states: progress in the management of complicating infections. Semin Hematol (1974) 2.89

Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood (1997) 2.82

Leukapheresis by continuous flow centrifugation (CFC) in patients with chronic myelocytic leukemia (CML). Blood (1969) 2.71

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71

Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol Cell Biol (1995) 2.62

Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med (1989) 2.61

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood (2001) 2.53

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood (2001) 2.52

Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med (1988) 2.44

Thermostable DNA polymerase chain amplification of t(14;18) chromosome breakpoints and detection of minimal residual disease. Proc Natl Acad Sci U S A (1988) 2.42

Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res (1998) 2.33

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 2.32

A novel interferon-inducible domain: structural and functional analysis of the human interferon regulatory factor 1 gene promoter. Mol Cell Biol (1993) 2.32

Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood (1999) 2.31

Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30

Cellular interactions in the proliferative response of human T and B lymphocytes to phytomitogens and allogeneic lymphocytes. J Exp Med (1974) 2.27

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia (2005) 2.24

Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol (1988) 2.24

A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood (1998) 2.17

Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17

Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14

A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11

Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood (1990) 2.09

Stimulatory capacity of human T and B lymphocytes in the mixed leukocyte culture. Nature (1974) 2.09

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood (1996) 2.06

Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04

Expansion by folinic acid of the peripheral blood progenitor pool after chemotherapy: its use in autografting in acute leukaemia. Br J Haematol (1990) 2.02

Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood (1992) 2.00

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood (1999) 1.99

Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation. Lancet (1992) 1.99

Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res (1996) 1.99

High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med (1987) 1.98

Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood (1999) 1.90

Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood (1988) 1.86

Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood (1985) 1.81

Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst (2000) 1.81

Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood (1997) 1.80

Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood (1995) 1.79

Management of infections in patients with leukemia and lymphoma: current concepts and experimental approaches. Semin Hematol (1972) 1.78

Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 1.72

Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med (1994) 1.71

Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood (1998) 1.69

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet (1995) 1.69

Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood (1989) 1.66

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64

Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors. J Clin Oncol (1996) 1.64

Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst (1997) 1.63

Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol (2001) 1.63

Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood (1991) 1.63

HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. Blood (1994) 1.62

Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant (1996) 1.62

Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med (1979) 1.61

Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood (1991) 1.61

Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med (1997) 1.59

Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood (1997) 1.57

Marrow toxicity of fractionated vs. single dose total body irradiation is identical in a canine model. Int J Radiat Oncol Biol Phys (1993) 1.57

Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood (1994) 1.57

Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med (1993) 1.55

Molecular rearrangement of the ALL-1 gene in acute myeloid leukemia without cytogenetic evidence of 11q23 chromosomal translocations. Cancer Res (1994) 1.54

Interferon-alpha-associated focal segmental glomerulosclerosis with massive proteinuria in patients with chronic myeloid leukemia following high dose chemotherapy. Cancer (1998) 1.52

A temperature-sensitive mutant of human p53. EMBO J (1994) 1.51

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother (1991) 1.49

Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood (1996) 1.49

Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant (1995) 1.47

Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood (1995) 1.45

High-dose cytosine arabinoside therapy for refractory leukemia. Blood (1983) 1.44

Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol (1989) 1.43

In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res (2000) 1.43

Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med (1981) 1.43

Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res (1996) 1.42

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia (2010) 1.42

Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood (2000) 1.41

High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol (1989) 1.41

The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation. Blood (2001) 1.41

Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation (2001) 1.41

Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria. N Engl J Med (1972) 1.41

Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med (1986) 1.41

Pharmacologic, toxicologic, and marrow transplantation studies in dogs given succinyl acetone. Transplantation (1992) 1.41

p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res (1995) 1.40

Treatment of acute myelogenous leukemia. An EBMT-EORTC retrospective analysis of chemotherapy versus allogeneic or autologous bone marrow transplantation. Eur J Cancer Clin Oncol (1989) 1.40

The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood (1993) 1.36

A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood (1991) 1.35

Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther (2009) 1.33

Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol (1989) 1.33

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol (1993) 1.32

Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood (1999) 1.31

Impaired cell-mediated immunity in Hodgkin's disease mediated by suppressor lymphocytes and monocytes. J Clin Invest (1978) 1.31

Stimulated lymphocyte cultures: responder recruitment and cell cycle kinetics. J Exp Med (1974) 1.29

Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. N Engl J Med (1977) 1.27

Sjögren-type syndrome after allogeneic bone-marrow transplantation. Ann Intern Med (1977) 1.27